로딩 중…
지수 로딩 중…
Nektar Therapeutics
NKTR· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$70.59-0.11%
2026-08-03
Financials
Valuation Metrics
Nektar Therapeutics's Market Cap is $2.38B. At end of 2025 it was $858M. Ranked #1936 of 3,112 in US market (top 62%), #721 of 1,445 on NASDAQ (top 50%), #118 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 44%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.38B | US#1,936/3,112 Sec#118/269 |
| Revenue | $56M | US#2,853/3,112 Sec#152/269 |
| Net Income | $-158M | US—/3,112 Sec—/269 |
| Total Assets | $763M | US#2,559/3,112 Sec#112/269 |
| Net Assets | $576M | US#2,148/3,112 Sec#98/269 |
| Value | ||
| P/B | 4.14x | US#2,005/3,112 Sec#121/269 |
| P/S | 42.87x | US#2,868/3,112 Sec#164/269 |
| FCF Yield | -8.55% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -27.44% | US#2,595/3,112 Sec#122/269 |
| ROA | -20.71% | US#2,783/3,112 Sec#126/269 |
| Op. Margin | -224.88% | US#2,867/3,112 Sec#144/269 |
| Revenue Growth | 3.83% | US#1,871/3,112 Sec#113/269 |
| Financial Health | ||
| Debt Ratio | 32.46% | US#360/3,112 Sec#110/269 |
| Total Debt | $143M | US#2,295/3,112 Sec#104/269 |
| FCF | $-204M | US#2,735/3,112 Sec#217/269 |
| Cash | $132M | US#2,030/3,112 Sec#155/269 |
| Current Ratio | 10.21x | US#247/3,112 Sec#79/269 |
| Performance | ||
| 1Y Return | 207.45% | US#100/3,112 Sec#31/269 |
| 1M Return | -0.63% | US#1,742/3,112 Sec#84/269 |
| From 52W High | -35.24% | US#2,372/3,112 Sec#181/269 |
| 1Y MDD | -46.54% | US#2,259/3,112 Sec#172/269 |
| Trading | ||
| Volume | 603,094 shares | US#1,922/3,112 Sec#190/269 |
| Trading Value | $42M | US#1,483/3,112 Sec#96/269 |
| Per Share | ||
| EPS | $-8.08 | US—/3,112 Sec—/269 |
| BPS | $4.43 | US#2,277/3,112 Sec#140/269 |